摘要
背景:CCAAT /增强子结合蛋白(C / EBPs)在不同发育阶段形成一系列转录因子,调节许多基因在多种细胞/组织/器官中的表达。通过它们与其同源DNA元件结合的能力和蛋白质 - 蛋白质相互作用,C / EBPs在生理和病理条件下调节多种功能,包括细胞分化,代谢和免疫应答,如建立血液谱系,维持正常生殖功能和恶性肿瘤的发展。 目的:本综述集中在C / EBP基因在血液恶性肿瘤和妇科器官和疾病中的作用和表观遗传学改变。对涉及C / EBP功能和调控的分子途径的新研究结果进行了回顾和分析。还讨论了这些发现的潜在治疗价值。 结论:C / EBP突变及其破坏野生型C / EBP肿瘤抑制活性的血液恶性肿瘤不同于C / EBP突变在妇科癌症中并不常见,引起了一些疑问, C / EBPs可能在妇科癌症中具有肿瘤抑制活性。然而,这个概念不能排除C / EBP的下调或DNA甲基化沉默的表观遗传学沉默可能有助于妇科恶性肿瘤发展的可能性。
关键词: CCAAT /增强子结合蛋白,C / EBP,妇科癌症,血液恶性肿瘤,高甲基化,表观遗传调节异常
Current Drug Targets
Title:CEBP Epigenetic Dysregulation as a Drug Target for the Treatment of Hematologic and Gynecologic Malignancies
Volume: 18 Issue: 10
关键词: CCAAT /增强子结合蛋白,C / EBP,妇科癌症,血液恶性肿瘤,高甲基化,表观遗传调节异常
摘要: Background: The CCAAT/enhancer binding proteins (C/EBPs) form a family of transcription factors regulating many genes’ expression in a variety of cells/tissues/organs at different developmental stages. With their capability of binding to their cognate DNA elements and through protein-protein interactions, C/EBPs modulate diverse functions including cell differentiation, metabolism, and immune response, under both physiological and pathological conditions such as the establishment of hematological lineages, the maintenance of normal reproductive function, and the development of malignancies.
Objectives: This review concentrates on the role(s) and epigenetic alterations of C/EBP genes in hematologic malignancies and gynecologic organs and disorders. New research findings on molecular pathways involved in C/EBP function and regulation are reviewed and analyzed. The potential therapeutic values of these findings are also discussed. Conclusion: Unlike in hematologic malignancies in which C/EBP mutations and their disruption of wild type C/EBP tumor suppressive activities have been well documented, mutation of C/EBP does not appear to be a common event in gynecologic cancers, raising some doubt if C/EBPs may have tumor suppressor activity in gynecologic cancers. However, this notion could not exclude the possibility that downregulation or DNA methylation-meditated epigenetic silencing of C/EBPs may contribute to the development of gynecologic malignancies.Export Options
About this article
Cite this article as:
CEBP Epigenetic Dysregulation as a Drug Target for the Treatment of Hematologic and Gynecologic Malignancies, Current Drug Targets 2017; 18 (10) . https://dx.doi.org/10.2174/1389450117666161228160455
DOI https://dx.doi.org/10.2174/1389450117666161228160455 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Comparative Proteomic Profiling of Extracellular Proteins between Normal and Gastric Cancer Cells
Current Cancer Drug Targets Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication
Current Drug Metabolism Passive Targeting of Cyclophosphamide-Loaded Carbonate Apatite Nanoparticles to Liver Impedes Breast Tumor Growth in a Syngeneic Model
Current Pharmaceutical Design Blockade of Neoangiogenesis, a New and Promising Technique to Control the Growth of Malignant Tumors and their Metastases
Current Vascular Pharmacology Dihydrofolate Reductase Gene Variations in Susceptibility to Disease and Treatment Outcomes
Current Genomics Genomics and Proteomics of Nucleoside Transporters
Current Pharmacogenomics Molecular Basis of Gestational Trophoblastic Diseases
Current Molecular Medicine Peptidyl Prolyl Isomerase, Pin1 is a Potential Target for Enhancing the Therapeutic Efficacy of Etoposide
Current Cancer Drug Targets Bestatin as an Experimental Tool in Mammals
Current Drug Metabolism Angiotensin II Receptor Blocker: Possibility of Antitumor Agent for Prostate Cancer
Mini-Reviews in Medicinal Chemistry Decreased Expression and Altered Methylation of Syncytin-1 Gene in Human Placentas Associated with Preeclampsia
Current Pharmaceutical Design An overview of ABC and SLC Drug Transporter Gene Regulation
Current Drug Metabolism Role of the Renin-Angiotensin System in Gynecologic Cancers
Current Cancer Drug Targets Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy
Current Cancer Drug Targets New Perspectives in Glioma Immunotherapy
Current Pharmaceutical Design Emulsomes Meet S-layer Proteins: An Emerging Targeted Drug Delivery System
Current Pharmaceutical Biotechnology miR-146a-5p Regulated Cell Proliferation and Apoptosis by Targeting SMAD3 and SMAD4
Protein & Peptide Letters The Characteristics, Functions and Inhibitors of Three Aminopeptidases Belonging to the M1 Family
Current Protein & Peptide Science Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design The Challenge of Exploiting ABCG2 in the Clinic
Current Pharmaceutical Biotechnology